Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cadrenal Therapeutics, Inc. ( (CVKD) ) is now available.
On December 10, 2025, Cadrenal Therapeutics acquired VLX-1005 and related assets from Veralox Therapeutics, enhancing its pipeline with a first-in-class drug candidate targeting immune signaling pathways in HIT. This acquisition, announced on December 11, 2025, positions Cadrenal to address the $40 billion global anticoagulation market and the $1 billion HIT market in the US and EU. VLX-1005, which has received Orphan Drug and Fast Track designations from the FDA, has shown promising results in Phase 1 and Phase 2 studies, potentially improving patient outcomes. The acquisition agreement includes upfront and milestone payments to Veralox, along with royalties on future global sales, enabling Cadrenal to focus on advancing VLX-1005’s clinical development.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to address limitations in current anticoagulation therapy. The company is engaged in creating products for rare and high-risk patient populations, with a pipeline that includes VLX-1005, a Phase 2 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), tecarfarin for patients with kidney dysfunction or left ventricular assist devices, and frunexian for acute hospital settings.
Average Trading Volume: 27,861
Technical Sentiment Signal: Sell
Current Market Cap: $20.7M
Learn more about CVKD stock on TipRanks’ Stock Analysis page.